Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emory University
• Collaborators: Georgia Center for Oncology Research & Education; Sanofi
• Treatments: Capecitabine; Docetaxel

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed breast carcinoma.

• Early stage breast cancer (stage 1, 2, 3).

• No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes.

• 18 years of age or older.

• Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Exclusion Criteria:

• Prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast cancer.

• Major surgery within 28 days of study entry.

• Evidence of central nervous system (CNS) metastases.

• Final eligibility for a clinical trial is determined by the health professionals conducting the trial.